by codm | Feb 21, 2024 | Newsletter
PARTICIPATION IN JCI RACE TO ZERO CIRCLE AND APPROVAL FOR SBT 1.5°C TARGET
For Print (PDF)
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito “Eisai”) announced today that it has received approval to participate in the Japan Climate Initiative (JCI) Race to Zero Circle, which commits to achieve net zero* by 2050, as part of its mid- and long-term initiatives to reduce greenhouse gas (GHG) emissions. Eisai also received approval for the SBT 1.5°C target, a new GHG reduction target, by “Science Based Targets (SBT) initiatives”, as outlined below.
Investor Contacts:
- 55% reduction of GHG emissions (Scope 1 and 2) by FY2030 (compared to FY2019).
- 27.5% reduction of GHG emissions (Scope 3 emissions based on purchased products and services) by FY2030 (compared to FY2019).
Scope 1: Direct emission of GHG released into the air by the use of fossil fuel
Scope 2: Indirect emission of GHG with use of electricity and steam purchased from others
Scope 3: Indirect emission of GHG by supply chain excluding Eisai
|
Upon the establishment of the Paris Agreement at the 21st Session of the Conference of the Parties (COP21) to the United Nations Framework Convention on Climate Change (UNFCCC) in December 2015, global common initiatives have been accelerated to the limit the global temperature rise to within 1.5°C of above pre-industrial levels (1.5°C target), and to by extension achieve net zero by 2050.
The need for immediate action to achieve the 1.5°C target was reaffirmed at the 28th Session of the Conference of the Parties (COP28) in December 2023. Eisai set a SBT 2.0°C target (30% reduction of GHG emissions by FY2030 compared to FY2016) in FY2019, achieving the goal for three consecutive years by FY2022, accomplishing a 60% reduction of emissions compared to the baseline FY2016 level. In order to achieve Net Zero by 2050, Eisai continues to strengthen its GHG reduction initiatives though the JCI Race to Zero Circle and the newly approved SBT 1.5°C target, as well as our continued commitment to the global initiative RE100.
Eisai’s corporate concept is to give first thought to patients and the people in the daily living domain, and increase the benefits that health care provides to them as well as meet their diversified healthcare needs worldwide. To realize this human health care (hhc) concept, it is essential to ensure the sustainability of the global environment, which is the basis of its business activities.
Eisai will promote its initiatives to mitigate climate change in line with its set goals in order to support people to “live their fullest lives” through ensuring social sustainability.
*Net Zero (the SBTi definition of net-zero)
- Reducing scope 1, 2, and 3 emissions to zero or to a residual level that is consistent with reaching net-zero emissions at the global or sector level in eligible 1.5°C -aligned pathways.
- Neutralizing any residual emissions at the net-zero target year and any GHG emissions released into the atmosphere thereafter.
Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120
[Notes to editors]
1. About The Japan Climate Initiative (JCI)
The Japan Climate Initiative (JCI) is a network committed to forging communication and the exchange of strategies and solutions among all actors, such as Japanese companies, local governments, research institutions and NGOs, that are implementing climate actions. JCI Race to Zero Circle is an official partner of Race To Zero, a global campaign promoted by the United Nations (UN).
Please refer to JCI website for further details.
2. About Race To Zero
Race To Zero is a global campaign rallying non-state actors – including companies, cities, regions, financial, educational, and healthcare institutions – to take rigorous and immediate action to achieve net zero by 2050 at the latest. Five criteria known as 5P’s (Pledge, Plan, Proceed, Publish and Persuade) apply to all members who join Race to Zero.
3. About Science Based Target (SBT) initiative
SBT initiative is an international joint initiative by CDP, which is a global non-governmental organization (NGO) running an environmental information disclosure program, the UN Global Compact (UNGC), the World Wide Fund for Nature (WWF) and the World Resources Institute (WRI). SBT is a set of science-based targets for Greenhouse Gas (GHG) reduction goals, which is reviewed and approved by the SBT initiative and globally embraced as a de facto standard.
Please refer to SBT initiative website for further details.
4. About Eisai’s Environmental Initiatives
The protection of the global environment, which is the foundation of our business activities, is not only an important, management issue for Eisai, but also has a significant impact on the lives of patients and the people in the daily living domain. It is also closely connected to Eisai’s contribution to social sustainability from a long-term perspective as stated in our Articles of Incorporation. Under “the ENW Environmental Protection Policy” and “Environmental Management Vision”, Eisai is committed to providing solutions to social issues by enhancing its environmental activities.
Please refer to our website for Eisai’s environmental commitments.
by codm | Feb 20, 2024 | Newsletter
For Print (PDF)
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that it has been selected for “Human Capital Leaders 2023” and “Human Capital Management Gold Quality” in the “Human Capital Survey 2023” jointly conducted by HR Technology Consortium, HR Research Institute (ProFuture Inc.) and MS&AD InterRisk Research & Consulting, Inc.
In the “Human Capital Survey 2023” (conducted between September and December 2023), 16 highly rated companies were selected for “Human Capital Management Gold Quality”, and 8 companies that were recognized by experts as having made particularly outstanding efforts were selected as “Human Capital Leaders 2023” out of approximately 500 participating companies and organizations. Eisai was highly evaluated for its unique initiatives, such as human capital management that is connected with its Articles of Incorporation, and straightforward communication on its social impact, as well as its proactive attitude on information disclosure including the use of its own performance indicators.
Eisai made a partial amendment to the Articles of Incorporation at an Ordinary General Meeting of Shareholders in 2022, adding “respecting human rights and diversity”, “providing full opportunities for growth to support self-fulfillment”, and “creating an employee-friendly environment” to “Ensuring stable employment”, which had previously been stipulated in it. The company has also reinforced its human resource initiatives, including the formulation of an “Integrated Human Resource Strategy”, with the pillars of “Wellbeing including health of employees”, “Diverse work style”, “Development and growth of employees”, and “Growth of the organization and businesses”, as well as introducing a compensation system based on employee roles in 2023, along with a personnel assessment system putting high value on employee actions with the aim of encouraging employees to grow autonomously and motivate them to serve in higher positions. Moreover, Eisai published the “Human Capital Report 2023” in July, 2023 that summarizes its human capital initiatives and KPI linked to its human resource strategies. Eisai promotes information disclosure regarding its initiatives on human capital management in its annual “Value Creation Report” and on its corporate website’s “Sustainability” section.
Eisai is seeking to provide impact to not only our shareholders, but various stakeholders throughout society including our customers and local communities by delivering new value to patients and the people in the daily living domain through the activities of our employees who are the only stakeholders who can directly contribute to our corporate concept, human health care.
Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120
by codm | Feb 15, 2024 | Newsletter
For Print (PDF)
Eisai Co., Ltd.
nippon medac Co., Ltd.
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and nippon medac Co., Ltd. (Headquarters: Tokyo, CEO: Hirohisa Iriyama, “nippon medac”), a subsidiary of medac Gesellschaft für klinische Spezialpräparate mbH (Headquarters: Germany, “medac GmbH”) announced today that they have obtained manufacturing and marketing approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) for the additional formulation of Metoject Subcutaneous Injection for the anti-rheumatic agent, pen-type autoinjector “Metoject® Subcutaneous Injection 7.5mg Pen 0.15mL, 10mg Pen 0.20mL, 12.5mg Pen 0.25mL and 15mg Pen 0.30mL” (methotrexate). Based on the license agreement signed by Eisai and medac GmbH in May 2019, nippon medac will hold the marketing authorization of Metoject, while Eisai will be responsible for product distribution of Metoject in Japan.
This formulation incorporates the previously MHLW-approved Metoject Subcutaneous Injection pre-filled syringe formulation in a pen-type autoinjector and was developed to reduce the burden on patients and improve safety during self-injection. The drug can be self-injected in two steps (1- removing the cap, 2- pressing the pen against the skin). The built-in needle cover prevents the needle from being seen prior to administration and automatically locks after administration to prevent accidental skin puncture.
It is estimated that there are approximately 700,000 – 800,000 rheumatoid arthritis patients in Japan,1 and methotrexate is used as the first-line option for the treatment of rheumatic arthritis. Eisai and nippon medac are committed to delivering this treatment option to reduce the burden on patients with rheumatoid arthritis, and will make further contributions to address the diversified needs of, and increase the benefits provided to, rheumatoid arthritis patients.
Media Inquiries:
[Notes to editors]
1. About Metoject® Subcutaneous Injection Pen (methotrexate)
Methotrexate (MTX) is positioned as the anchor drug for rheumatoid arthritis treatment.2 For rheumatoid arthritis, it is believed that MTX regulates cell growth by inhibiting folate metabolism in lymphocytes and other cells, and also has an anti-inflammatory mechanism through the promotion of adenosine synthesis in vascular endothelial cells and other cells in synovial membranes. Metoject Subcutaneous Injection Pen will be the first self-administrable MTX subcutaneous injection pen-type autoinjector for rheumatoid arthritis in Japan. It is approved in more than 16 countries in Europe.
2. About Eisai
Eisai’s Corporate Concept is “to give first thought to patients and people in the daily living domain, and to increase the benefits that health care provides.” Under this Concept (also known as our human health care (hhc) Concept), we aim to effectively achieve social good in the form of relieving anxiety over health and reducing health disparities. With a global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to create and deliver innovative products to target diseases with high unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology.
In addition, our continued commitment to the elimination of neglected tropical diseases (NTDs), which is a target (3.3) of the United Nations Sustainable Development Goals (SDGs), is demonstrated by our work on various activities together with global partners.
For more information about Eisai, please visit www.eisai.com (for global headquarters: Eisai Co., Ltd.), and connect with us on X, LinkedIn and Facebook.
3. About nippon medac
nippon medac Co., Ltd. was established in April 2016 as the Japanese subsidiary of medac GmbH. We are working to develop new drugs that can expand treatment options for diseases for which therapeutic requirements have not yet been fully met. We will work diligently to deliver quality drugs as quickly as possible to improve the quality of life of patients and their families in areas with high medical need.
1 Report from Study Committee on Rheumatoid Arthritis and Allergy
http://www.mhlw.go.jp/stf/houdou/2r9852000001nfao-att/2r9852000001nfdx.pdf
2 Japan College of Rheumatology, Clinical practice guideline of methotrexate for patients with rheumatoid arthritis: 2016 updated version
by codm | Feb 3, 2024 | Journey
In partnership with the Child Neuroscience Center of Philippine Children Medical Center (PCMC), HI-Eisai implemented a way to better understand the situation of children with epilepsy as well as their parents and caregivers. There may be a lack of awareness of this condition in the community as patients look physically normal, but they experience hard-to-control seizures that impair their quality of life.
Brush for Freedom (BFF) was developed so we can continuously support the patients and their families in their journey to seizure freedom.
Engaging with Young Epilepsy Patients
To be able to interact with patients and their families, a fun and creative painting session for the children was set in place, “Paint Your Feelings, Dreams and Future”. The activity fostered creativity and self-esteem, and gave the children the opportunity to freely express their thoughts and feelings.
After the activity, the most artistic and expressive artwork was recognized and featured in HI-Eisai’s internal forum along with the child’s story. The paintings were also showcased in the seizure diary provided to our partner healthcare professionals to increase awareness and encourage proper management of epilepsy.
Encouraging Patients to Interact with Each Other
“Shake It Off” is a fun-filled activity where patients socialized with one another through games, dancing, and singing to celebrate their oneness in their journey to seizure freedom. Parents, caregivers, healthcare professionals, and HI-Eisai members also engaged through a simple fellowship.
by codm | Feb 3, 2024 | Journey
HI-Eisai strives to improve the quality of life of patients with dementia by promoting awareness and empowering patients. In line with this, Memories Re-imagined was conceptualized.
Memories Re-imagined is an activity among senior citizens where they were given the opportunity to reminisce and relive the past; a way to look back and recapture precious memories that may have brought meaning in their lives, as well as reflect on their younger selves and their achievements.
Reconnecting with the past and sharing of experiences helped the patients boost their self-esteem, giving them a feeling of importance and being valued.
The activities conducted include dementia screening (MMSE), Dementia Lecture to increase awareness, as well as a Photo Shoot Session where patients recreated a fond memory of an old photo of their choice. Reimagining and listening to the patients’ stories through the photos helped us understand and appreciate their journey, as each of us can relate to how memories shape and mold our lives.
